舒尼替尼治疗晚期肾癌的疗效及不良反应单中心分析

摘要

Objective To anaLyse the efficacy and side‐effect of sunitinib in the treatment of advanced renaL carcinoma in a singLe center . Methods A retrospective anaLysis was made for meta‐static renaL ceLL carcinoma (mRCC) patients treated with sunitinib from Sep .2012 to Jan .2016 in Af‐fiLiated HospitaL of Qingdao University .T wenty‐eight patients received sunitinib 50 mg Qd ,4／2 weeks scheduLe primariLy ,2 patients received 50 mg Qd ,2／1 weeks scheduLe and 1 patient received 37?5 mg Qd . ResuLts T wenty‐six maLe and 5 femaLe patients were anaLyzed .Four cases were CR (12?9%) ,2 cases were PR(6?5%) ,15 cases were SD (48?4%) and 10 cases were PD (32?3%). Disease controL rate was 67?7% .T he main side‐effect incLuded hand‐foot syndrome (90?3%) ,fa‐tigue (87?1%) ,hypogeusia(77?4%) ,etc.Side‐effect of 1‐2 grade was found in 80?6% patients . ConcLusions As the first‐Line therapy for patients with mRCC ,sunitinib can gain high disease con‐troL rate and sLight‐to‐miLd side‐effect ,w hich is safe and weLL toLerated .%目的 分析舒尼替尼对于晚期肾癌患者的疗效及不良反应. 方法 2012年9月至2016年1月于青岛大学附属医院泌尿外科接受舒尼替尼治疗的31例晚期肾癌患者纳入研究,其中单发转移灶24例、多发转移灶7例.接受舒尼替尼50 mg 4／2方案28例,37?5 mg持续给药方案1例,50 mg 2／1方案2例.总结分析其疗效和不良反应等. 结果 完全缓解4例(12?9%) 、部分缓解2例(6?5%) 、疾病平稳15例(48?4%) 、疾病进展10例(32?3%) ,疾病控制率67?7%.主要不良反应有手足综合征(90?3%) 、乏力(87?1%)和味觉减退(77?4%)等.轻度不良反应率80?6%.结论 舒尼替尼治疗晚期肾癌可获得较高的疾病控制率,不良反应多数较轻且易耐受.